• Iche Andriyani Liberty Department of Public Health and Community Medicine, Medical Faculty of Sriwijaya University, Palembang, Indonesia.
  • Nasrin Kodim 2Department of Epidemiology, Public Health Faculty of Universitas Indonesia, Depok, Indonesia.


 Objective: Prediabetes is a high-risk condition for diabetes development and several other health outcomes later in life, but little is known about the factors associated with this condition. On the other hand, by predicting the risk of prediabetes, it is also a golden period for prevent or delay the diabetes conversion. The aim here was to assess the prevalence, risk factor that associated, and build a model to assess prediabetes risk.

Methods: A cross-sectional study was conducted in Palembang, Indonesia. Data were collected during January until May 2016. We recruited adult age >15 years from 16 districts in Palembang. Anthropometric, demographic, and clinical history data were measured by standard methods. Capillary blood glucose was measured by finger prick test, followed by confirmatory oral glucose tolerance tests.

Results: Of a total of 1241 participants, the prevalence of prediabetes was 27.8% (345 participants) and 72.2% (896 participants) and those were normal blood glucose. Employment, age, exercise, alcohol consumption, body mass index, systolic pressure, diastolic pressure, waist circumference, and hypercholesterol history were screened out as independent factors to build the prediction risk model.

Conclusion: The prediabetes prediction model can be used easily and understood by health-related users to assess prediabetes risk. The intervention program, designed based on our prediabetes model to prevent or delay the conversion of prediabetes to diabetes in the population. The discovery of pharmacological therapies to prevent further conversion is needed.


Keywords: Assess, Prediction, Prediabetes, Risk.


1. Florencia A, Alex B, Ho CN, Gisela D, Sheree D, Trisha D, et al. IDF Diabetes Atlas. 6th ed. Basel, Switzerland: International Diabetes Federation; 2013.
2. Jansson SP, Andersson DK, Svärdsudd K. Mortality trends in subjects with and without diabetes during 33 years of follow-up. Diabetes Care 2010;33:551-6.
3. Wermeling PR, Gorter KJ, van Stel HF, Rutten GE. Both cardiovascular and non-cardiovascular comorbidity are related to health status in well-controlled type 2 diabetes patients: A cross-sectional analysis. Cardiovasc Diabetol 2012;11:121.
4. Harris MI, Klein R, Welborn TA, Knuiman MW. Onset of NIDDM occurs at least 4-7 yearr before clinical diagnosis. J Diabetes Care 1992;15(7):815-9.
5. Medrano MJ, Pastor-Barriuso R, Boix R, del Barrio JL, Damián J, Alvarez R, et al. Coronary disease risk attributable to cardiovascular risk factors in the Spanish population. Rev Esp Cardiol 2007;60(12):1250-6.
6. Díaz-Redondo A, Giráldez-García C, Carrillo L, Serrano R, García- Soidán FJ, Artola S, et al. Modifiable risk factors associated with prediabetes in men and women: A cross-sectional analysis of the cohort study in primary health care on the evolution of patients with prediabetes (PREDAPS-Study). BMC Fam Pract 2015;16:5.
7. Nathan DM, Davidson MB, DeFronzo RA, Heine RJ, Henry RR, Pratley R, et al. Impaired fasting glucose and impaired glucose tolerance: Implications for care. Diabetes Care 2007;30(3):753-9.8. Matos LN, Giorelli Gde V, Saado A, Dias CB. Prevalence of prediabetes in patients with metabolic risk. Sao Paulo Med J 2011;129(5):300-8.
9. Alberti KG, Zimmet P, Shaw J; IDF Epidemiology Task Force Consensus Group. The metabolic syndrome – A new worldwide definition. Lancet 2005;366(9491):1059-62.
10. Tuomilehto J, Lindström J, Eriksson JG, Valle TT, Hämäläinen H, Ilanne-Parikka P, et al. Prevention of Type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344(8):1343-50.
11. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2010;33 Suppl 1:S62-9.
12. Ouyang P, Guo X, Shen Y, Lu N, Ma C. A simple score model to assess prediabetes risk status based on the medical examination data. Can J Diabetes 2015;40(5):419-23.
13. Segura J, Roldán C, García-Donaire JA, Ruilope LM. Prediabetes and cardiovascular risk in hypertensive patients. Curr Hypertens Rep 2006;8(2):97-100.
14. Annis AM, Caulder MS, Cook ML, Duquette D. Family history, diabetes, and other demographic and risk factors among participants of the National Health and Nutrition Examination Survey 1999-2002. Prev Chronic Dis J 2005;2(2):A19.
15. Chien KL, Hsu HC, Su TC, Chang WT, Chen PC, Chen MF, et al. Sibling and parental history in Type 2 diabetes risk among ethnic Chinese: The Chin-Shan community cardiovascular cohort study. Eur J Cardiovasc Prev Rehabil 2008;15(6):657-62.
16. Zhang Y, Chen H, Lu H, Shen Y, Chen R, Fang P, et al. Prevalence and risk of diabetes based on family history in the Shanghai High-Risk Diabetic Screen (SHiDS) study. Diabet Med 2016;33(12):1705-11.
17. Zhang L, Guo Z, Wu M, Hu X, Xu Y, Zhou Z. Interaction of smoking and metabolic syndrome on cardiovascular risk in a Chinese cohort. Int J Cardiol 2003;167(1):250-3.
18. Agostino RB, Hamman RF, Karter AJ, Mykkanen L, Wagenknecht LE, Haffner SM. Cardiovascular disease risk factors predict the development of Type 2 diabetes: The insulin resistance atherosclerosis study.Diabetes Care J 2004;27(9):2234-40.
19. Ruhembe CC, Mosha TC, Nyaruhucha CN. Prevalence and awareness of Type 2 diabetes mellitus among adult population in Mwanza city, Tanzania. Tanzan. J Health Res 2014;16(2):1-11.
20. Tabák AG, Herder C, Rathmann W, Brunner EJ, Kivimäki M. Prediabetes and the risk of diabetes - Authors’ reply. Lancet 2012;380(9849):1226.
21. Venkates G, Jayprakash A, Swathi KS. The effect of sun light exposure on prediabetic patients in south indian population. Int J Pharm Pharm Sci 2014;6(11):107-10.
22. DeLuca HF. Overview of general physiologic features and functions of vitamin D. Am J Clin Nutr 2004;80(6):1689-96.
23. Verma RK, Tripathi P, Pandey AK. Role of pioglitazone on progression of atherosclerosis in prediabetes: A mini review. Int J Pharm Pharm Sci 2014;6(2):13-5.
307 Views | 431 Downloads
How to Cite
Liberty, I. A., and N. Kodim. “ASSESS PREDIABETES RISK, AS A GOLDEN PERIOD FOR PREVENTION OF DIABETES”. Asian Journal of Pharmaceutical and Clinical Research, Vol. 10, no. 6, June 2017, pp. 349-53, doi:10.22159/ajpcr.2017.v10i6.18215.
Original Article(s)